COVID-19 reinfection: the role of natural immunity, vaccines, and variants

References

• World Health Organization Coronavirus Disease (COVID-19) Dashboard. [cited 2021 Feb 24] https://covid19.who.int
   Google Scholar
• Kellam P, Barclay W. The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection. J Gen Virol. 2020;101(8):791–797.
   PubMed Web of Science ®Google Scholar
• Interim guidance on duration of isolation and precautions for adults with COVID-10. Centers for Disease Control and Prevention. [cited 2021 Jun 6] https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html. Published March 16, 2021.
   Google Scholar
• Victor Okhuese A. Estimation of the probability of reinfection with COVID-19 by the susceptible-Exposed-Infectious-Removed-Undetectable-Susceptible model. JMIR Public Health Surveill. 2020;6(2):e19097.
   PubMedGoogle Scholar
• Malkov E. Simulation of coronavirus disease 2019 (COVID-19) scenarios with possibility of reinfection. Chaos Solitons Fractals. 2020;139:110296.
   Web of Science ®Google Scholar
• Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021; 27(4): 601-615.
   Web of Science ®Google Scholar
• Gomes MG, White LJ, Medley GF. Infection, reinfection, and vaccination under suboptimal immune protection: epidemiological perspectives. J Theor Biol. 2004;228(4):539–549.
   PubMed Web of Science ®Google Scholar
• Arafkas M, Khosrawipour T, Kocbach P, et al. Current meta-analysis does not support the possibility of COVID-19 reinfections. J Med Virol. 2020;93(3):1599-1604.
   Web of Science ®Google Scholar
• SARS-CoV-2 Cycle Threshold: A Metric That Matters (or Not). American Association for Clinical Chemistry. [cited 2021 Jun 7] https://www.aacc.org/cln/cln-stat/2020/december/3/sars-cov-2-cycle-threshold-a-metric-that-matters-or-not. Updated December 3, 2020.
   Google Scholar
• Hall V, Foulkes S, Charlett A, et al. Do antibody positive healthcare workers have lower SARS-CoV-2 infection rates than antibody negative healthcare workers? Large multi-centre prospective cohort study (the SIREN study), England: June to November 2020. medRxiv. 2021.01.13.21249642
   Google Scholar
• Hansen CH, Michlmayr D, Gubbels SM, et al. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study. Lancet. 2021;397(10280):1204–1212.
   PubMed Web of Science ®Google Scholar
• Abu-Raddad LJ, Chemaitelly H, Coyle P, et al. SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy. EClinicalMedicine. 2021;35:100861.
   PubMedGoogle Scholar
• Koyama T, Platt D, Parida L. Variant analysis of SARS-CoV-2 genomes. Bull World Health Organ. 2020;98(7):495–504.
   PubMed Web of Science ®Google Scholar
• Kirkcaldy RD, King BA, Brooks JT. COVID-19 and postinfection immunity: limited evidence, many remaining questions. Jama. 2020;323(22):2245–2246.
   PubMed Web of Science ®Google Scholar
• SARS-CoV-2 Variant Classifications and Definitions. Centers for disease control and prevention. [cited 2021 Jun 5] https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html. Published June 4, 2021.
   Google Scholar
• Variant Proportions. Centers for disease control and prevention. [cited 2021 Jul 28] https://covid.cdc.gov/covid-data-tracker/#variant-proportions. Published July 27, 2021.
   Google Scholar
• Tillett RL, Sevinsky JR, Hartley PD, et al. Genomic evidence for reinfection with SARS-CoV-2: a case study. Lancet Infect Dis. 2020;21(1):52-58.
   Web of Science ®Google Scholar
• Larson D, Brodniak SL, Voegtly LJ, et al. A case of early re-infection with SARS-CoV-2. Clin Infect Dis. 2020.Sep 19:ciaa1436
   Google Scholar
• Goldman JD, Wang K, Roltgen K, et al. Reinfection with SARS-CoV-2 and failure of humoral immunity: a case report. medRxiv. 2020.09.22.20192443
   Google Scholar
• To KK, Hung IF, Ip JD, et al. COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing. Clin Infect Dis. 2020.Aug 25:ciaa1275
   Web of Science ®Google Scholar
• Van Elslande J, Vermeersch P, Vandervoort K, et al. Symptomatic SARS-CoV-2 reinfection by a phylogenetically distinct strain. Clin Infect Dis. 2021;73(2):354-356
   Web of Science ®Google Scholar
• Selhorst P, Van Ierssel S, Michiels J, et al. Symptomatic SARS-CoV-2 reinfection of a health care worker in a Belgian nosocomial outbreak despite primary neutralizing antibody response. Clin Infect Dis. 2020. DOI:https://doi.org/10.1093/cid/ciaa1850.
   Google Scholar
• Prado-Vivar B, Becerra-Wong M, Guadalupe JJ, et al. A case of SARS-CoV-2 reinfection in Ecuador. Lancet Infect Dis. 2021;21(6):e142.
   Google Scholar
• Marquez L, Koy T, Spinler JK, et al. Reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.1.7 variant in an immunocompromised adolescent. Infect Control Hosp Epidemiol. 2021;1–2. doi: https://doi.org/10.1017/ice.2021.195
   Google Scholar
• Shastri J, Parikh S, Agrawal S, et al. Clinical, serological, whole genome sequence analyses to confirm SARS-CoV-2 reinfection in patients from Mumbai, India. Front Med (Lausanne). 2021;8:631769.
   PubMed Web of Science ®Google Scholar
• Sevillano G, Ortega-Paredes D, Loaiza K, et al. Evidence of SARS-CoV-2 reinfection within the same clade in Ecuador: a case study. Int J Infect Dis. 2021;108:53–56.
   PubMed Web of Science ®Google Scholar
• Mattiuzzi C, Henry BM, Sanchis-Gomar F, et al. SARS-CoV-2 recurrent RNA positivity after recovering from coronavirus disease 2019 (COVID-19): a meta-analysis. Acta Biomed. 2020;91(3):e2020014.
   PubMedGoogle Scholar
• Ye G, Pan Z, Pan Y, et al. Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivation. J Infect. 2020;80(5):e14–e7.
   PubMed Web of Science ®Google Scholar
• Li Y, Yao L, Li J, et al. Stability issues of RT-PCR testing of SARS-CoV-2 for hospitalized patients clinically diagnosed with COVID-19. J Med Virol. 2020;92(7):903–908.
   PubMed Web of Science ®Google Scholar
• Sethuraman N, Jeremiah SS, Ryo A. Interpreting diagnostic tests for SARS-CoV-2. Jama. 2020;323(22):2249–2251.
   PubMed Web of Science ®Google Scholar
• Arkhipova-Jenkins I, Helfand M, Armstrong C, et al. Antibody response after SARS-CoV-2 infection and implications for immunity: a rapid living review. Ann Intern Med. 2021;174(6):811–821.
   Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Interim guidelines for COVID-19 antibody testing. August 1, 2020. [cited 2021 Jan 1] Available at: https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html
   Google Scholar
• Kang CK, Kim M, Lee S, et al. Longitudinal analysis of human memory T-Cell response according to the severity of Illness up to 8 months after SARS-CoV-2 infection. J Infect Dis. 2021;224(1):39–48.
   Web of Science ®Google Scholar
• Liu A, Li Y, Peng J, et al. Antibody responses against SARS-CoV-2 in COVID-19 patients. J Med Virol. 2021;93(1):144-148.
   Web of Science ®Google Scholar
• Iyer AS, Jones FK, Nodoushani A, et al. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Sci Immunol. 2020;Oct 8;5(52):eabe0367.
   Web of Science ®Google Scholar
• Yao L, Wang GL, Shen Y, et al. Persistence of antibody and cellular immune responses in COVID-19 patients over nine months after infection. J Infect Dis. 2021. May 12:jiab255.
   Google Scholar
• To KK, Hung IF, Chan KH, et al. Serum antibody profile of a patient with COVID-19 reinfection. Clin Infect Dis. 2021;72(10):e659-e662.
   Google Scholar
• Dai L, Gao GF. Viral targets for vaccines against COVID-19. Nat Rev Immunol. 2021;21(2):73-82.
   Web of Science ®Google Scholar
• Knoll MD, Wonodi C. Oxford-AstraZeneca COVID-19 vaccine efficacy. Lancet. 2021;397(10269):72–74.
   PubMed Web of Science ®Google Scholar
• Administration USFD. Janssen COVID-19 Vaccine. U.S. Food & Drug Administration. [cited 2021 Mar 7] 2021. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/janssen-covid-19-vaccine. Published.
   Google Scholar
• Kay C. Homegrown Indian covid vaccine already in use shows 78% efficacy. Bloomberg. [cited 2021 Jun 7] https://www.bloomberg.com/news/articles/2021-04-21/homegrown-indian-covid-vaccine-already-in-use-shows-78-efficacy. Updated April 21, 2021
   Google Scholar
• About Vaccine. Sputnik V. https://sputnikvaccine.com/about-vaccine Published. 2021.
   Google Scholar
• Baraniuk C. What do we know about China’s covid-19 vaccines? Bmj. 2021;373:n912.
   PubMedGoogle Scholar
• Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(2):181–192.
   PubMed Web of Science ®Google Scholar
• Wu Z, Hu Y, Xu M, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(6):803–812.
   PubMed Web of Science ®Google Scholar
• Staff R. Sinopharm’s COVID-19 vaccine 79% effective, seeks approval in China. Reuters. Middle East & Africa Web site. cited 2021 May 30 https://www.reuters.com/article/health-coronavirus-china-vaccine-int-idUSKBN2940CA. Published 2021. Updated December 29, 2020.
   Google Scholar
• Covid-19 vaccines made by China’s Sinopharm, CanoSino release efficacy data. Science Website. https://www.scmp.com/news/china/science/article/3122980/covid-19-vaccines-made-chinas-sinopharm-cansino-release-efficacy. Updated May 30, 2021. [cited 2021 May 30]
   Google Scholar
• Novavax COVID-19 vaccine demonstrates 89.3% efficacy in UK phase 3 trial. Novavax. [cited 2021 May 30] https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3. Updated January 28, 2021.
   Google Scholar
• Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397(10287):1819–1829.
   PubMed Web of Science ®Google Scholar
• Connor BA, Couto-Rodriguez M, Barrows JE, et al. Monoclonal antibody therapy in a vaccine breakthrough SARS-CoV-2 hospitalized delta (B.1.617.2) variant case. Int J Infect Dis. 2021;110:232–234.
   Web of Science ®Google Scholar
• Sheikh A, McMenamin J, Taylor B, et al. SARS-CoV-2 delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet. 2021 Jun 26;397(10293):2461–2462.
   PubMed Web of Science ®Google Scholar
• Xie X, Liu Y, Liu J et al. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Nat Med. 2021; 27(4)620-621. 
   Google Scholar
• Abu-Raddad LJ, Chemaitelly H, Butt AA. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. N Engl J Med. 2021;385(2):187–189.
   Web of Science ®Google Scholar
• Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (delta) variant. N Engl J Med. 2021;385(7):585–594.
   PubMed Web of Science ®Google Scholar